MK-677

MK-677 (ibutamoren mesylate) is an orally bioavailable, non-peptide small molecule that acts as an agonist at the ghrelin receptor (GHSR1a). It stimulates endogenous growth-hormone release through the same receptor that natural ghrelin uses, raising serum GH and downstream IGF-1 to levels typical of younger adults.

Despite being classified with peptides in most online discussions, MK-677 is not a peptide. It is a spiropiperidine compound discovered at Merck Research Laboratories in the 1990s and assigned the internal codes L-163,191 and MK-0677. Oral bioavailability is around 60 to 80 percent, which is the feature that distinguishes it from every other GH secretagogue: no injection required. The plasma half-life is approximately 4 to 6 hours, but the GH-releasing effect lasts roughly 24 hours per oral dose, supporting once-daily administration.

Merck discontinued internal development around 2007. In September 2018, Lumos Pharma licensed the compound and renamed it LUM-201 for its current Phase 2 program in pediatric growth hormone deficiency. Across the full development history, MK-677 has been administered to more than 1,200 subjects in published trials, including approximately 200 children and 1,000 adult and elderly patients. That is a substantial Phase 2 dataset by peptide-class standards.

The Published Trial Evidence

Five trial programs make up most of the published MK-677 dataset. None established clinical efficacy for an adult indication.

Svensson et al., 1998. 24 obese men, 25 mg daily for 8 weeks. IGF-1 increased by approximately 40 percent. Fat-free mass increased. Total body fat and visceral fat were unchanged. This was the trial that disproved the "MK-677 burns fat" claim before the claim became popular online. Obese men with increased IGF-1 did not lose fat over 8 weeks.

Bach et al., 2004 / Adunsky et al., Maturitas 2010. 123 patients aged 65 and older recovering from hip fracture, 25 mg daily for 24 weeks. IGF-1 increased by 84 percent. Gait speed improved by 0.7 points (p = 0.011). Stair-climbing power did not meaningfully change (p = 0.292). Most measures of physical function were unchanged. The trial was halted early because 4 of 62 patients (6.5%) on MK-677 developed congestive heart failure, versus 1 of 61 (1.7%) on placebo. The mechanism most reviews invoke is GH-mediated fluid retention unmasking subclinical cardiac dysfunction in a vulnerable elderly population.

Sevigny et al., 2008. Patients with mild-to-moderate Alzheimer's disease, 25 mg daily for 12 months. IGF-1 increased by 60.1 percent at 6 weeks and 72.9 percent at 12 months. Cognitive endpoints did not improve. The program was discontinued.

Nass et al., Annals of Internal Medicine, 2008. 65 healthy older adults aged 60 to 81, 25 mg daily for 2 years in a modified crossover design. Fat-free mass increased by 1.1 kg over the 2-year period. Strength and functional performance did not improve. Body cell mass increased by 0.8 kg with MK-677 versus a decrease of 1.0 kg on placebo. Cortisol increased by an average of 47 nmol/L (1.7 µg/dL, p = 0.020). Fasting glucose rose modestly. Insulin sensitivity declined.

LUM-201 pediatric program (Lumos Pharma, ongoing). Phase 2 trials in children with growth hormone deficiency. The pediatric indication makes mechanistic sense because the receptor signaling is intact in this population, and the regulatory pathway for pediatric orphan drugs is more workable than the adult anti-aging or sarcopenia path that Merck abandoned. Phase 3 data has not been published as of May 2026.

The pattern across the adult trials is consistent. IGF-1 rises. Fat-free mass increases modestly, largely through water content and intracellular volume rather than contractile tissue. Strength does not improve. Fat loss does not occur. Glucose rises. Cortisol rises. Edema is common.

MK-677 binds the growth hormone secretagogue receptor 1a (GHSR1a) in the hypothalamus and pituitary. GHSR1a is the receptor for ghrelin, the gut-secreted "hunger hormone" that also has GH-releasing activity. Activation triggers a GH pulse from pituitary somatotrophs. The pulse pattern is dose-dependent and largely preserves the normal feedback architecture, which is why MK-677 does not produce the sustained supraphysiological GH levels associated with exogenous rhGH.

The downstream cascade is the same as with GHRH analogs: GH release drives hepatic IGF-1 synthesis, and IGF-1 mediates most of the anabolic, lipolytic, and tissue-repair effects attributed to the drug. The replicable finding across MK-677 trials is IGF-1 increase. Reported magnitudes range from 40 percent at 8 weeks in obese men (Svensson 1998) to 60 percent at 6 weeks (Sevigny 2008) to 84 percent in the hip-fracture cohort (Bach 2004) to 72.9 percent sustained at 12 months in older adults (Nass 2008).

What MK-677 does not do is bypass the secondary regulatory loops. GH and IGF-1 increases do not always translate into the downstream outcomes that users care about, particularly strength and clinically meaningful fat loss. That gap between biomarker response and clinical effect is the most consistent finding in the literature and the most frequently overlooked in lay discussion.

This compound is on the World Anti-Doping Agency (WADA) Prohibited List under sections S0 and S2. Use in competitive sport is a doping violation in-competition and out-of-competition.

IGF-1 Response (Replicable)

The most consistent finding across MK-677 trials is sustained IGF-1 increase. The magnitude varies by population and baseline.

Svensson 1998 (obese men, 25 mg daily, 8 weeks): IGF-1 increased approximately 40 percent.

Bach/Adunsky 2004 (elderly hip-fracture, 25 mg daily, 24 weeks): IGF-1 increased 84 percent.

Sevigny 2008 (Alzheimer's, 25 mg daily, 12 months): IGF-1 increased 60.1 percent at 6 weeks, 72.9 percent at 12 months.

Nass 2008 (older adults, 25 mg daily, 2 years): IGF-1 sustained at supraphysiological levels for the full 2-year duration.

The IGF-1 response is dose-dependent in the 5 to 50 mg daily range tested. Doses above 25 mg do not produce proportionally larger IGF-1 responses, because pituitary GH output is rate-limited by stored GH availability rather than by ghrelin receptor activation alone.

Body Composition Effects (Inconsistent)

The body composition findings across published trials are smaller than what users typically expect and largely consistent across populations.

Fat-free mass. Increases of 1 to 2 kg over months to years of use. The Nass 2008 trial documented a 1.1 kg fat-free mass increase over 2 years (placebo group decreased 1.0 kg, for a 2.1 kg between-group difference).

Composition of the fat-free mass gain. Most of the increase appears to come from intracellular water and edema rather than contractile muscle protein. The body cell mass increase (a proxy for metabolically active tissue) was 0.8 kg in Nass 2008, smaller than the total fat-free mass change.

Total body fat. Unchanged in Svensson 1998 and Nass 2008. Despite 40 to 73 percent IGF-1 increase, neither trial showed fat-mass reduction.

Visceral fat. Unchanged in Svensson 1998 in obese men. This is the same population where tesamorelin Phase 3 trials documented meaningful visceral fat reduction. The disparity is one reason MK-677 has not been positioned as a body-composition drug despite the GH-class mechanism.

Strength and Functional Performance (No Improvement)

Nass 2008 documented no improvement in strength or physical function over 2 years in older adults despite sustained IGF-1 elevation. Bach 2004 showed a modest 0.7-point gait speed improvement (p = 0.011) but no meaningful change in stair-climbing power or other functional measures. The translation from IGF-1 increase to strength has not occurred in any published MK-677 trial.

Appetite and Weight

Increased appetite is the most consistent subjective finding. Ghrelin is the hunger hormone, and MK-677 activates the same receptor. Users typically report measurable appetite increase within the first weeks of use. Total body weight tends to increase if food intake is not actively restricted, with the gain split between fat-free mass (some real, some water) and fat mass.

Sleep Quality

Improved depth and continuity of sleep is one of the most commonly reported subjective effects, often appearing within the first week of use. The mechanistic basis is plausible because GH release is closely linked with slow-wave sleep architecture. Polysomnographic studies in MK-677 are limited.

Glucose and Insulin Sensitivity

The Nass 2008 trial reported modest fasting glucose increase and declining insulin sensitivity over 2 years. The magnitude is small in healthy subjects but clinically meaningful in patients with prediabetes or type 2 diabetes. The mechanism is the standard GH-induced insulin resistance pattern seen with all GH secretagogues.

Cortisol

The Nass 2008 trial documented cortisol increase of 47 nmol/L (1.7 µg/dL, p = 0.020) above baseline. Mechanism is incompletely characterized but appears related to GHSR1a activity in the hypothalamus. Some users report subjective effects of slightly elevated stress response or sleep disruption that may be related.

Cardiac Signal in Vulnerable Elderly

The Bach 2004 / Adunsky 2010 congestive heart failure signal (6.5 percent on MK-677 vs 1.7 percent on placebo) is the most serious documented adverse event in the MK-677 literature. The signal has not been replicated in younger or healthier cohorts and is presumed to relate to fluid retention unmasking subclinical cardiac compromise in elderly hip-fracture patients. Whether the same signal would appear in younger users with covert cardiac vulnerability is unknown.

What MK-677 Does NOT Affect

Several commonly attributed effects are not supported by the published evidence.

Testosterone, LH, FSH. MK-677 does not affect the hypothalamic-pituitary-gonadal axis. Trial data shows no change in testosterone, LH, or FSH at any dose tested.

Hepatotoxicity. Liver enzymes have not consistently risen above normal in published trials. MK-677 does not cause the cholestatic or hepatocellular injury pattern of oral anabolic steroids.

Fat loss. Documented unchanged in Svensson 1998 and Nass 2008.

Strength gain. Documented absent in Nass 2008 over 2 years.

Standard Phase 2 Dose

The dose used in nearly every Merck Phase 2 trial was 25 mg orally once daily. This dose produced the IGF-1 increases described above and is the dose that defined the published evidence base for MK-677 in adults. Trial duration ranged from 8 weeks (Svensson 1998) to 2 years (Nass 2008) at the same 25 mg daily dose.

Dose Range Tested

Earlier dose-finding studies tested 5 mg, 10 mg, 25 mg, and 50 mg orally once daily. The dose-response curve plateaus around 25 mg. Doses above 25 mg do not produce proportionally larger IGF-1 responses, because pituitary GH output is rate-limited. The 25 mg dose is the standard for adult Phase 2 work for this reason.

Pediatric LUM-201 Dosing

The Lumos Pharma pediatric program uses 0.8 mg/kg/day in children with growth hormone deficiency. For a 30 kg child, this corresponds to approximately 24 mg daily, comparable to the adult 25 mg dose by mass. The pediatric trials titrate based on weight rather than using a fixed adult dose.

Pharmacokinetics

MK-677 has a plasma half-life of approximately 4 to 6 hours. Peak plasma concentration occurs 1 to 3 hours after oral administration. The drug is metabolized primarily through CYP3A4 in the liver. Despite the relatively short plasma half-life, the GH-releasing effect lasts roughly 24 hours per oral dose, which is why once-daily administration is sufficient.

Oral bioavailability is approximately 60 to 80 percent. Food does not substantially affect absorption, which is why MK-677 can be taken with or without meals. Steady-state IGF-1 response builds over approximately 2 to 4 weeks of consistent daily dosing.

Timing

MK-677 can be taken at any time of day. The choice of bedtime administration in many off-label protocols is based on the rationale of aligning the GH pulse with the natural nocturnal pulse during slow-wave sleep. Morning or daytime administration produces the same GH effect but without amplifying the natural nocturnal peak. Patients who report MK-677-induced lethargy or sedation often switch to bedtime dosing to avoid daytime impact.

Off-Label Adult Compounded Use (Pre-Category 2)

Before the September 2023 Category 2 placement, adult off-label MK-677 was available through compounding pharmacies and through research-chemical channels at the following typical doses.

Standard adult protocol: 25 mg orally once daily, matching the Merck Phase 2 dose.

Lower-dose protocols: 10 mg or 12.5 mg daily, used in patients with insulin resistance, edema sensitivity, or cardiovascular risk factors.

Higher-dose protocols: Doses of 30 to 50 mg daily have been used in research-chemical settings without trial-based justification. The flat dose-response above 25 mg means higher doses likely produce no additional IGF-1 benefit and increase the rate of side effects.

Cycling Patterns

Adult off-label MK-677 protocols typically use cycling of 8 to 16 weeks on followed by 4 to 8 weeks off. The rationale is theoretical, based on concern about sustained ghrelin receptor activation and on the desire to maintain insulin sensitivity. No published human pharmacokinetic data demonstrates that cycling produces better IGF-1 outcomes or fewer side effects than continuous use. The Nass 2008 trial maintained continuous daily dosing for 2 years with no apparent cycling-related issue, suggesting the cycling rationale is not strongly evidence-based.

Detection Window

WADA-accredited laboratories use validated mass-spectrometry methods that detect ibutamoren and its metabolites for at least 2 to 4 days post-administration in urine. The plasma detection window is shorter (1 to 2 days). The relatively short detection window compared with peptide GH secretagogues reflects the small-molecule nature of MK-677 and its CYP3A4-mediated metabolism.

Why Adult MK-677 Has Not Been Re-Submitted to FDA

Merck completed Phase 2 trials in five separate adult indications (sarcopenia, hip fracture recovery, Alzheimer's disease, obesity, frailty) without identifying a population where MK-677 produced clinically meaningful outcomes. The combination of robust IGF-1 increase without corresponding functional improvement, plus the cardiac signal in vulnerable elderly populations, eliminated the commercial rationale for further Merck development. Lumos Pharma has pursued the pediatric GHD path instead because pediatric growth velocity is a more direct biomarker-to-outcome translation than adult sarcopenia or anti-aging endpoints.

The published Phase 2 data describes a fairly consistent adverse-event profile.

Increased appetite. Documented in nearly every trial. This is the ghrelin-receptor effect and is generally pronounced in the first weeks of dosing. Users typically gain weight if they do not actively restrict food intake.

Edema and fluid retention. GH-mediated effect on sodium and water handling. Reported in 10 to 20 percent of subjects across the Bach 2004 and Nass 2008 cohorts. Peripheral edema and bloating are the typical presentations.

Lethargy. Some users report a "drugged" or sedated sensation, particularly during dose escalation. The mechanism is unclear but is consistent with reports of ghrelin's broader effects on hypothalamic signaling.

Insulin resistance and glucose increase. Documented across multiple trials. Fasting glucose rises modestly. Insulin sensitivity declines. The magnitude is small in healthy subjects but clinically meaningful in patients with prediabetes or type 2 diabetes.

Cortisol increase. Reported in Nass 2008 at 47 nmol/L above baseline (p = 0.020). Mechanism is incompletely characterized but appears related to GHSR1a activity in the hypothalamus.

Congestive heart failure in vulnerable elderly. The Bach 2004 signal is the most serious documented adverse event in the MK-677 literature. The signal has not been replicated in younger or healthier cohorts, and the mechanism is presumed to be fluid retention in patients with subclinical cardiac compromise.

Theoretical cancer risk. Sustained IGF-1 increase is epidemiologically associated with increased risk of breast, prostate, and colorectal cancers in the general population. No MK-677 trial has shown an increased cancer signal, but the trials were too small and too short to test this question.

The competitive advantage of MK-677 over peptide GH secretagogues is oral bioavailability. Sermorelin, CJC-1295 (with or without DAC), ipamorelin, GHRP-2, GHRP-6, hexarelin, and tesamorelin all require subcutaneous injection. MK-677 is a once-daily tablet. For users who avoid injectable protocols, this matters.

The Phase 2 data does not show that MK-677 is more effective than injectable GHRH analogs at producing IGF-1 increase or weight effects. The closest comparator is tesamorelin, which has FDA approval for HIV lipodystrophy and a complete Phase 3 file showing visceral-fat reduction. No head-to-head trial comparing MK-677 with tesamorelin has been published.

For sarcopenia and frailty in aging adults, MK-677 was the front-running candidate through the 2000s and failed to translate IGF-1 increase into strength or function. The same population is now being studied with selective androgen receptor modulators, myostatin inhibitors, and exercise-based protocols. The pharmacological GH-secretagogue path has not produced a viable adult anti-aging drug in 20 years of attempts.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.